Ontorpacept
- Generic Name
- Ontorpacept
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2131089-46-6
- Unique Ingredient Identifier
- Q8A4U1Z9N2
- Associated Conditions
- -
- Associated Therapies
- -
TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Recurrent ALK Positive Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma Associated with Chronic InflammationRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular LymphomaRecurrent High Grade B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 62
- Registration Number
- NCT05507541
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath